Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Approved Endocrinology Drugs in Clinical Development in CHINA

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              BeiGene

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

              Contact the Supplier

              Lead Product(s): Denosumab

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Amgen Inc

              Deal Size: $2,800.0 million Upfront Cash: $2,800.0 million

              Deal Type: Collaboration January 02, 2020

              Details:

              The stratagic collaboration between Amgen and BeiGene will significantly accelerate Amgen's plans to expand its oncology presence in China.

              PharmaCompass__DigitalAd